Phreesia [PHR] vs 10x Genomics [TXG] Detailed Stock Comparison

Phreesia

NYSE
Loading...

10x Genomics

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 18 vital metrics comparison: Phreesia wins in 8 metrics, 10x Genomics wins in 9 metrics, with 0 ties. 10x Genomics appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricPhreesia10x GenomicsBetter
P/E Ratio (TTM)N/A-8.55N/A
Price-to-Book Ratio5.342.0510x Genomics
Debt-to-Equity Ratio2.6011.22Phreesia
PEG Ratio-40.100.05Phreesia
EV/EBITDA-27.85-11.07Phreesia
Profit Margin (TTM)-13.94%-13.13%10x Genomics
Operating Margin (TTM)-46.68%-2.63%10x Genomics
Return on Equity-22.67%-11.30%10x Genomics
Return on Assets (TTM)-8.75%-9.45%Phreesia
Free Cash Flow (TTM)$8.29M$-6.73MPhreesia
1-Year Return11.86%-22.26%Phreesia
Price-to-Sales Ratio (TTM)3.412.4610x Genomics
Enterprise Value$986.85M$1.23B10x Genomics
EV/Revenue Ratio2.351.9010x Genomics
Gross Profit Margin (TTM)69.40%72.34%10x Genomics
Revenue per Share (TTM)$7$5Phreesia
Earnings per Share (Diluted)$-1.02$-0.7010x Genomics
Beta (Stock Volatility)0.742.05Phreesia
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Phreesia vs 10x Genomics Stock Performance Analysis

Loading Price Chart...

Phreesia
10x Genomics
Phreesia Stock Overview | 10x Genomics Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Phreesia0.90%-0.30%-12.32%-17.29%-2.81%-6.79%
10x Genomics-0.86%11.46%-9.26%6.04%66.75%-10.92%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Phreesia11.86%4.45%-28.41%-2.17%-2.17%-2.17%
10x Genomics-22.26%-50.59%-92.28%-75.82%-75.82%-75.82%

News Based Sentiment: Phreesia vs 10x Genomics

Phreesia

News based Sentiment: POSITIVE

Phreesia’s Q3 2025 results significantly exceeded expectations, and the company provided optimistic guidance for FY2026. This, combined with positive analyst ratings and industry recognition, paints a positive picture for investors, suggesting a potential turnaround in the company’s performance.

View Phreesia News Sentiment Analysis

10x Genomics

News based Sentiment: MIXED

October brought a strong Q3 earnings beat and positive analyst revisions for 10x Genomics, but these were tempered by a negative full-year EPS forecast and mixed technical indicators. This creates a complex investment picture with both opportunities and risks, making it a significant month for the company.

View 10x Genomics News Sentiment Analysis

Performance & Financial Health Analysis: Phreesia vs 10x Genomics

MetricPHRTXG
Market Information
Market Cap i$1.43B$1.59B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i403,2302,746,660
90 Day Avg. Volume i422,9132,469,420
Last Close$23.48$12.64
52 Week Range$17.07 - $32.76$6.78 - $20.92
% from 52W High-28.33%-39.58%
All-Time High$81.59 (Feb 08, 2021)$208.99 (Jun 28, 2021)
% from All-Time High-71.22%-93.95%
Growth Metrics
Quarterly Revenue Growth0.46%0.13%
Quarterly Earnings Growth0.15%0.13%
Financial Health
Profit Margin (TTM) i-0.14%-0.13%
Operating Margin (TTM) i-0.47%-0.03%
Return on Equity (TTM) i-0.23%-0.11%
Debt to Equity (MRQ) i2.6011.22
Cash & Liquidity
Book Value per Share (MRQ)$4.51$6.21
Cash per Share (MRQ)$7.48$3.59
Operating Cash Flow (TTM) i$32.38M$66.95M
Levered Free Cash Flow (TTM) i$28.64M$58.22M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend i$0.00N/A

Valuation & Enterprise Metrics Analysis: Phreesia vs 10x Genomics

MetricPHRTXG
Price Ratios
P/E Ratio (TTM) iN/A-8.55
Forward P/E i-40.10-10.45
PEG Ratio i-40.100.05
Price to Sales (TTM) i3.412.46
Price to Book (MRQ) i5.342.05
Market Capitalization
Market Capitalization i$1.43B$1.59B
Enterprise Value i$986.85M$1.23B
Enterprise Value Metrics
Enterprise to Revenue i2.351.90
Enterprise to EBITDA i-27.85-11.07
Risk & Other Metrics
Beta i0.742.05
Book Value per Share (MRQ) i$4.51$6.21

Financial Statements Comparison: Phreesia vs 10x Genomics

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)PHRTXG
Revenue/Sales i$109.68M$154.88M
Cost of Goods Sold i$33.57M$49.44M
Gross Profit i$76.12M$105.45M
Research & Development i$29.63M$64.25M
Operating Income (EBIT) i$-7.61M$-48.53M
EBITDA i$2.03M$-32.89M
Pre-Tax Income i$-5.38M$-33.51M
Income Tax i$1.01M$852,000
Net Income (Profit) i$-6.39M$-34.36M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)PHRTXG
Cash & Equivalents i$84.22M$377.06M
Total Current Assets i$203.29M$579.73M
Total Current Liabilities i$114.02M$107.90M
Long-Term Debt i$8.80M$70.63M
Total Shareholders Equity i$264.81M$706.90M
Retained Earnings i$-801.50M$-1.50B
Property, Plant & Equipment i$17.24M$55.58M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)PHRTXG
Operating Cash Flow i$15.59M$35.44M
Capital Expenditures i$-2.79M$-1.89M
Free Cash Flow i$9.20M$32.46M
Debt Repayment i$-2.64MN/A
Common Stock Repurchase i$0N/A

Short Interest & Institutional Ownership Analysis

MetricPHRTXG
Shares Short i2.34M17.35M
Short Ratio i4.777.58
Short % of Float i0.05%0.22%
Average Daily Volume (10 Day) i403,2302,746,660
Average Daily Volume (90 Day) i422,9132,469,420
Shares Outstanding i58.73M122.29M
Float Shares i56.03M109.33M
% Held by Insiders i0.04%0.02%
% Held by Institutions i0.97%1.05%

Dividend Analysis & Yield Comparison: Phreesia vs 10x Genomics

MetricPHRTXG
Last 12-Month Dividend i$0.00N/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend i$0.00N/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends i$0.00N/A
Ex-Dividend DateN/AN/A